Literature DB >> 22081191

Prevalence and antimicrobial susceptibility of enterococcus species isolated from clinical specimens.

S Akhter1, Z H Asna, M M Rahman.   

Abstract

Multidrug-resistant enterococci are emerging as a leading nosocomial pathogen. Knowledge of the antimicrobial resistance profile is essential to formulate treatment guidelines for infection caused by enterococci. A total of 200 enterococcal strains were isolated from various clinical specimens from May 2009 to April 2010 in the Department of Microbiology, Bangladesh Institute of Health Sciences Hospital, Mirpur, Dhaka, Bangladesh. They were speciated and an antimicrobial susceptibility pattern was determined. E. faecalis (75.5%) was the most common species in all clinical specimens followed by E. faecium (7.5%) and E. duranes (3.5%). Polymicrobial infection was found in 24(12%) of the cases. The maximum susceptibility was observed with vancomycin (100%) followed by linezolid (96%), imipenem and nitrofurantoin (95%). About 30% high level aminoglycoside resistance (HLAR) was found in this study.

Entities:  

Mesh:

Year:  2011        PMID: 22081191

Source DB:  PubMed          Journal:  Mymensingh Med J        ISSN: 1022-4742


  3 in total

1.  Absence of vancomycin-resistant enterococci among highly ESBL-positive crows (Corvus splendens) foraging on hospital waste in Bangladesh.

Authors:  Badrul Hasan; Josef D Järhult
Journal:  Infect Ecol Epidemiol       Date:  2015-12-15

2.  Antimicrobial susceptibility of enterococcal species isolated from antibiotic-treated dogs and cats.

Authors:  Yasushi Kataoka; Yurie Umino; Hiroki Ochi; Kazuki Harada; Takuo Sawada
Journal:  J Vet Med Sci       Date:  2014-06-30       Impact factor: 1.267

3.  Increasing Prevalence of Aminoglycoside-Resistant Enterococcus faecalis Isolates Due to the aac(6')-aph(2") Gene: A Therapeutic Problem in Kermanshah, Iran.

Authors:  Mitra Khani; Mahdie Fatollahzade; Hamid Pajavand; Somaye Bakhtiari; Ramin Abiri
Journal:  Jundishapur J Microbiol       Date:  2016-03-12       Impact factor: 0.747

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.